Innate Pharma News Headlines (NASDAQ:IPHA)

$5.25

+0.15 (+2.94 %)

(As of 03/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$4.90

Now: $5.25▼

$5.40

50-Day Range

$3.80

MA: $6.47▼

$7.95

52-Week Range

$3.30

Now: $5.25▼

$8.24

Volume7,423 shs

Average VolumeN/A

Market Capitalization$401.84 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Innate Pharma (NASDAQ IPHA) News Headlines

Source:

Date	Headline
	Contrasting Innate Pharma (IPHA) & Its Peers www.americanbankingnews.com - March 29 at 3:50 AM
	Head-To-Head Analysis: Innate Pharma (IPHA) and Its Competitors www.americanbankingnews.com - March 23 at 10:48 PM
	Innate Pharma (IPHA) vs. Its Competitors Head-To-Head Contrast www.americanbankingnews.com - March 21 at 6:18 AM
	Contrasting Innate Pharma (IPHA) & The Competition www.americanbankingnews.com - March 18 at 8:48 AM
	Innate Pharma S.A. (NASDAQ:IPHA) Given $11.50 Consensus Target Price by Brokerages www.americanbankingnews.com - March 14 at 12:01 PM
	Contrasting Innate Pharma (IPHA) and Its Rivals www.americanbankingnews.com - March 13 at 10:07 PM
	Innate Pharma S.A. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? finance.yahoo.com - March 13 at 8:07 AM
	First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors finance.yahoo.com - March 10 at 7:36 AM
	IPHA LOSS NOTICE: ROSEN LAW FIRM, NATIONAL... www.benzinga.com - February 10 at 11:07 PM
	IPHA LOSS NOTICE: ROSEN LAW FIRM, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Innate Pharma S.A.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – IPHA finance.yahoo.com - February 10 at 11:07 PM
	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm finance.yahoo.com - February 3 at 10:33 PM
	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm finance.yahoo.com - January 31 at 1:10 PM
	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm www.businesswire.com - January 29 at 8:49 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA finance.yahoo.com - January 29 at 6:14 PM
	EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A. – IPHA finance.yahoo.com - January 29 at 6:14 PM
	Should You Be Excited About Innate Pharma S.A.'s (EPA:IPH) 17% Return On Equity? finance.yahoo.com - January 17 at 8:32 AM
	French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides finance.yahoo.com - January 13 at 8:44 PM
	French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides finance.yahoo.com - January 13 at 8:44 PM
	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Innate Pharma S.A. (IPHA) finance.yahoo.com - January 10 at 4:47 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA www.globenewswire.com - January 10 at 1:21 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA finance.yahoo.com - January 10 at 1:21 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA www.benzinga.com - January 9 at 10:31 PM
	FDA places Innate Pharma lacutamab study on partial clinical hold seekingalpha.com - January 9 at 9:10 AM
	Why This Hairy Cell Leukemia Treatment Could Be Big in Europe 247wallst.com - January 3 at 4:34 PM
	Innate Pharma up 27% premarket on EMA acceptance of Lumoxiti application seekingalpha.com - January 3 at 4:34 PM
	Innate Pharma Rallies On Acceptance Of European Regulatory Application For Leukemia Drug www.benzinga.com - January 3 at 4:34 PM